Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240)
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Intraoperative photodynamic therapy (PDT) with 5-aminolevulinic acid hydrochloride (5-ALA HCl) shows promise for glioblastoma treatment, improving survival rates and quality of life. This approach, combined with surgery and adjuvant therapy, offers a potential new avenue for managing this incurable cancer.
Area Of Science
- Neurosurgery
- Oncology
- Photomedicine
Background
- Glioblastoma is an aggressive brain tumor with poor prognosis despite standard treatments.
- Optimal multimodal management for glioblastoma has limited efficacy.
- There is a need for novel therapeutic strategies to improve patient outcomes.
Purpose Of The Study
- To report updated, exploratory analyses of overall survival (OS), progression-free survival (PFS), and health-related quality of life (HRQOL).
- To evaluate the efficacy and safety of intraoperative photodynamic therapy (PDT) with 5-aminolevulinic acid hydrochloride (5-ALA HCl) in glioblastoma patients.
- To assess the long-term outcomes of a standardized therapeutic approach combining 5-ALA HCl fluorescence-guided surgery (FGS) and intraoperative PDT.
Main Methods
- A single-arm, open-label pilot trial (INDYGO) included ten glioblastoma patients.
- Patients underwent 5-ALA HCl FGS followed by intraoperative PDT (200 J/cm²).
- Adjuvant therapy (Stupp protocol) was administered postoperatively, with follow-up every 3 months.
Main Results
- Median follow-up was 23 months; no unacceptable toxicities or treatment-related deaths occurred.
- Actuarial 12-month PFS rate was 60%, with a median OS of 23.4 months.
- Actuarial 12-month, 24-month, and 5-year OS rates were 80%, 50%, and 40%, respectively.
Conclusions
- Intraoperative PDT, combined with maximal surgical excision and adjuvant treatment, appears to increase time to recurrence and overall survival in glioblastoma patients.
- Health-related quality of life was maintained throughout the study without severe side effects.
- The findings suggest PDT is a safe and potentially effective adjunctive therapy for glioblastoma.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.